Windtree Therapeutics, based in Philadelphia, is a biotechnology company dedicated to developing innovative therapies for respiratory diseases, oncology, and cardiovascular conditions. Founded with a mission to deliver groundbreaking treatments and hope for patients with significant unmet medical needs, Windtree focuses on KL4 surfactant therapies and other novel compounds. Their product pipeline includes Istaroxime, a first-in-class dual mechanism therapy designed to enhance cardiac function by improving both systolic contractions and diastolic relaxation.

Notable figures associated with Windtree Therapeutics include experienced leaders in the biotech industry and key investors who have supported the company's growth. The company is publicly traded on NASDAQ under the ticker symbol WINT. Windtree has achieved significant milestones in advancing its clinical trials and expanding its therapeutic portfolio, making a substantial impact on addressing critical health challenges. Their innovative approach continues to drive progress in treating complex medical conditions, offering new hope to patients worldwide.